Monitoring SARS-CoV-2 antibody status after immunization

With the ongoing vaccination programmes, the level of immunisation becomes of vital significance. The detection of both SARS-CoV-2 IgG and neutralizing antibodies are the methods of choice for the screening of patients after the vaccination.

We offer the following kits for this purpose:

• WANWS-1596 WANTAI SARS-COV-2 NABS ELISA (NEUTRALIZING ANTIBODIES) CE IVD
  • This ELISA is a surrogate assay and is an aid in the screening of patients suspected for infection with SARS-CoV-2 virus or after vaccination.
  • It is calibrated against the WHO-Standard: NIBSC 20/136
  • Results are quantified

 

• WANWS-1396 WANTAI SARS-COV-2 IGG ELISA KIT (QUANTITATIVE) CE IVD.
  • This ELISA is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection, or as an aid in individual vaccination management decisions.
  • It is calibrated against the WHO-Standard: NIBSC 20/136
  • Results are quantified

 

• WANWJ-3050 WANTAI SARS-COV-2 IGG RAPID TEST (SEMI-QUANTITATIVE) CE IVD.
  • A lateral flow assay for the semi-quantitative detection of IgG antibody.

 

March 24, 2021